{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:44:11Z","timestamp":1773798251179,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-05705-z","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T10:01:46Z","timestamp":1710583306000},"page":"5681-5690","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study"],"prefix":"10.1007","volume":"103","author":[{"given":"Naokazu","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyoshi","family":"Arima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhito","family":"Takakuwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Imada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Fuchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Uoshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Hanamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohiko","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Shimazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Hino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Kansai Myeloma Forum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,16]]},"reference":[{"key":"5705_CR1","doi-asserted-by":"publisher","unstructured":"F E Davies. C Pawlyn, S Z Usmani, et al. (2022) Perspective on the Risk-Stratified Treatment of Multiple Myeloma. Blood Cancer Discov. OF1-OF12. https:\/\/doi.org\/10.1158\/2643-3230.BCD-21-0205.","DOI":"10.1158\/2643-3230.BCD-21-0205"},{"issue":"22","key":"5705_CR2","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.1158\/1078-0432.CCR-16-0625","volume":"22","author":"KC Anderson","year":"2016","unstructured":"Anderson KC (2016) Progress and Paradigms in Multiple Myeloma. Clin Cancer Res 22(22):5419\u20135427","journal-title":"Clin Cancer Res"},{"issue":"5","key":"5705_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","volume":"12","author":"P Hagen","year":"2022","unstructured":"Hagen P, Zhang J, Barton K (2022) High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. Blood Cancer J 12(5):83","journal-title":"Blood Cancer J"},{"issue":"2","key":"5705_CR4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11899-021-00624-6","volume":"16","author":"H Hosoya","year":"2021","unstructured":"Hosoya H, Sidana S (2021) Antibody-Based Treatment Approaches in Multiple Myeloma. Curr Hematol Malig Rep 16(2):183\u2013191","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"5705_CR5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1177\/2040620716657993","volume":"7","author":"H Einsele","year":"2016","unstructured":"Einsele H, Schreder M (2016) Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab. Ther Adv Hematol 7(5):288\u2013301","journal-title":"Ther Adv Hematol"},{"key":"5705_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2147\/ITT.S306103","volume":"10","author":"HN Abramson","year":"2021","unstructured":"Abramson HN (2021) Immunotherapy of Multiple Myeloma: Promise and Challenges. Immunotargets Ther 10:343\u2013371","journal-title":"Immunotargets Ther"},{"key":"5705_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03177-6","author":"J Panaampon","year":"2022","unstructured":"Panaampon J, Kariya R, Okada S (2022) Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells. Cancer Immunol Immunother. https:\/\/doi.org\/10.1007\/s00262-022-03177-6","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"5705_CR8","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1158\/2326-6066.CIR-18-0579","volume":"7","author":"T Pazina","year":"2019","unstructured":"Pazina T, James AM, Colby KB et al (2019) Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma. Cancer Immunol Res 7(10):1633\u20131646","journal-title":"Cancer Immunol Res"},{"key":"5705_CR9","doi-asserted-by":"publisher","first-page":"25551","DOI":"10.3389\/fimmu.2018.02551","volume":"9","author":"KS Campbell","year":"2018","unstructured":"Campbell KS, Cohen AD, Pazina T (2018) Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody. Elotuzumab in Multiple Myeloma Front Immunol 9:25551. https:\/\/doi.org\/10.3389\/fimmu.2018.02551","journal-title":"Elotuzumab in Multiple Myeloma Front Immunol"},{"issue":"9","key":"5705_CR10","doi-asserted-by":"publisher","first-page":"e1339853","DOI":"10.1080\/2162402X.2017.1339853","volume":"6","author":"T Pazina","year":"2017","unstructured":"Pazina T, James AM, MacFarlane AW 4th et al (2017) The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and independent mechanisms. Oncoimmunology 6(9):e1339853. https:\/\/doi.org\/10.1080\/2162402X.2017.1339853","journal-title":"Oncoimmunology"},{"issue":"7","key":"5705_CR11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A et al (2015) Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med 373(7):621\u2013631","journal-title":"N Engl J Med"},{"issue":"15","key":"5705_CR12","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1182\/bloodadvances.2020002440","volume":"5","author":"AB Bigley","year":"2021","unstructured":"Bigley AB, Spade S, Agha NH et al (2021) Fc\u03b5RI\u03b3-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma. Blood Adv 5(15):3021\u20133031","journal-title":"Blood Adv"},{"issue":"10","key":"5705_CR13","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-20-3418","volume":"27","author":"H Cho","year":"2021","unstructured":"Cho H, Kim KH, Lee H et al (2021) Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma. Clin Cancer Res 27(10):2947\u20132958","journal-title":"Clin Cancer Res"},{"key":"5705_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3031","author":"A Bruzzese","year":"2022","unstructured":"Bruzzese A, Derudas D, Galli M et al (2022) Elotuzumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. Hematol Oncol. https:\/\/doi.org\/10.1002\/hon.3031","journal-title":"Hematol Oncol"},{"issue":"8","key":"5705_CR15","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328-346","journal-title":"Lancet Oncol"},{"issue":"15","key":"5705_CR16","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412\u20133420","journal-title":"J Clin Oncol"},{"issue":"3","key":"5705_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"5705_CR18","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K et al (2016) Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med 375(8):754\u2013766","journal-title":"N Engl J Med"},{"issue":"10","key":"5705_CR19","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Hulin C, Perrot A et al (2021) Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomized, phase 3 trial. Lancet Oncol 22(10):1378\u20131390","journal-title":"Lancet Oncol"},{"issue":"6","key":"5705_CR20","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M et al (2018) Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med 378(6):518\u2013528","journal-title":"N Engl J Med"},{"issue":"1","key":"5705_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/cells9010167","volume":"9","author":"I Saltarella","year":"2020","unstructured":"Saltarella I, Desantis V, Melaccio A et al (2020) Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. Cells 9(1):167","journal-title":"Cells"},{"key":"5705_CR22","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","volume":"9","author":"NW van de Donk","year":"2018","unstructured":"van de Donk NW, Usmani SZ (2018) CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. Front Immunol 9:2134. https:\/\/doi.org\/10.3389\/fimmu.2018.02134","journal-title":"Front Immunol"},{"issue":"1","key":"5705_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","volume":"9","author":"L Sanchez","year":"2016","unstructured":"Sanchez L, Wang Y, Siegel DS et al (2016) Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol 9(1):51","journal-title":"J Hematol Oncol"},{"issue":"2","key":"5705_CR24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3324\/haematol.2010.030759","volume":"96","author":"MS van der Veer","year":"2011","unstructured":"van der Veer MS, de Weers M, van Kessel B et al (2011) Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 96(2):284\u2013290","journal-title":"Haematologica"},{"issue":"12","key":"5705_CR25","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3390\/cells8121522","volume":"8","author":"TG Martin","year":"2019","unstructured":"Martin TG, Corzo K, Chiron M et al (2019) Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. Cells 8(12):1522","journal-title":"Cells"},{"issue":"9","key":"5705_CR26","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1182\/blood.2020008209","volume":"137","author":"M Dimopoulos","year":"2021","unstructured":"Dimopoulos M, Bringhen S, Anttila P et al (2021) Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed\/refractory multiple myeloma. Blood 137(9):1154\u20131165","journal-title":"Blood"},{"issue":"5","key":"5705_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41408-021-00478-4","volume":"11","author":"J Mikhael","year":"2021","unstructured":"Mikhael J, Belhadj-Merzoug K, Hulin C, Vincent L, Moreau P et al (2021) A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J 11(5):89","journal-title":"Blood Cancer J"},{"issue":"12","key":"5705_CR28","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.3390\/cancers13123072","volume":"13","author":"M Lejeune","year":"2021","unstructured":"Lejeune M, Duray E, Peipp M et al (2021) Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma. Cancers 13(12):3072","journal-title":"Cancers"},{"issue":"21","key":"5705_CR29","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1182\/blood.2020006200","volume":"136","author":"MN Kararoudi","year":"2020","unstructured":"Kararoudi MN, Nagai Y, Elmas E et al (2020) CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood 136(21):2416\u20132427","journal-title":"Blood"},{"issue":"1","key":"5705_CR30","doi-asserted-by":"publisher","first-page":"5159","DOI":"10.1038\/s41598-023-32426-6","volume":"13","author":"Y Shimazu","year":"2023","unstructured":"Shimazu Y, Kanda J, Kosugi S et al (2023) Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa\/lambda ratio or B2 microglobulin. Sci Rep 13(1):5159","journal-title":"Sci Rep"},{"key":"5705_CR31","doi-asserted-by":"crossref","unstructured":"Garajales-Cruz AF, et al. (2019) Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and\/or Daratumumab: A Single-Institution Analysis. Blood 2019 Nov; 134(Supplement_1): 3183.","DOI":"10.1182\/blood-2019-129021"},{"key":"5705_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","volume":"70","author":"P Robak","year":"2018","unstructured":"Robak P, Drozdz I, Szemraj J et al (2018) Drug resistance in multiple myeloma. Cancer Treat Rev 70:199\u2013208","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"5705_CR33","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","volume":"128","author":"IS Nijhof","year":"2016","unstructured":"Nijhof IS, Casneuf T, van Velzen J et al (2016) CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood 128(7):959\u2013970","journal-title":"Blood"},{"issue":"5","key":"5705_CR34","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/ejh.13046","volume":"100","author":"M Pick","year":"2018","unstructured":"Pick M, Vainstein V, Goldschmidt N et al (2018) Daratumumab resistance is frequent in advanced stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis. Eur J Haematol 100(5):494\u2013501","journal-title":"Eur J Haematol"},{"issue":"23","key":"5705_CR35","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","volume":"1","author":"T Casneuf","year":"2017","unstructured":"Casneuf T, Steven X, Adams HC 3rd (2017) Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv 1(23):2105\u20132114","journal-title":"Blood Adv"},{"key":"5705_CR36","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1200\/JCO.2007.12.8298","volume":"26","author":"D Canioni","year":"2008","unstructured":"Canioni D, Salles G, Mounier N et al (2008) High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin. Oncol 26:440\u2013446","journal-title":"J Clin. Oncol"},{"key":"5705_CR37","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1158\/1078-0432.CCR-11-0239","volume":"17","author":"J Pander","year":"2011","unstructured":"Pander J, Heusinkveld M, van der Straaten T et al (2011) Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Can Res 17:5668\u20135673","journal-title":"Clin Can Res"},{"key":"5705_CR38","doi-asserted-by":"crossref","unstructured":"Biswas SK, Mantovani A. (2011) Macrophage plasticity and interaction with lymphocyte subsets: cancer as paradigm. Nat. Immunol. 889\u2013896.","DOI":"10.1038\/ni.1937"},{"issue":"5","key":"5705_CR39","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.4049\/jimmunol.1301249","volume":"192","author":"S Herter","year":"2014","unstructured":"Herter S, Birk MC, Klein C et al (2014) Glycoengineering of Therapeutic Antibodies Enhances Monocyte\/Macrophage-Mediated Phagocytosis and Cytotoxicity. J Immunol 192(5):2252\u20132260","journal-title":"J Immunol"},{"key":"5705_CR40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1034\/j.1600-065X.2001.1800116.x","volume":"180","author":"M Kirschfink","year":"2001","unstructured":"Kirschfink M (2001) Targeting complement in therapy. Immunol Rev 180:177\u2013189","journal-title":"Immunol Rev"},{"issue":"10","key":"5705_CR41","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nri2620","volume":"9","author":"PF Zipfel","year":"2009","unstructured":"Zipfel PF, Skerka C (2009) Complement regulators and inhibitory proteins. Nat Rev Immunol 9(10):729\u2013740","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"5705_CR42","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.4161\/mabs.29670","volume":"6","author":"S Meyer","year":"2014","unstructured":"Meyer S, Leusen JH, Boross P (2014) Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. MAbs 6(5):1133\u20131144","journal-title":"MAbs"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05705-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05705-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05705-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:05:51Z","timestamp":1735866351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05705-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,16]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["5705"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05705-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,16]]},"assertion":[{"value":"30 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee of the KMF and Shinko Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"TT received honoraria from Sanofi K.K. and Janssen Pharmaceutical K.K. and grants from Bristol-Myers Squibb Co., Incyte Biosciences Japan G.K., GSK Corp. and Pfizer Japan Inc. SF received personal fees from Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K. and Sanofi K.K. JK received honoraria from Bristol-Myers Squibb Co., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co., Ltd., Sanofi K.K. and Ono Pharmaceutical Co., Ltd. and is in advisory roles at Janssen Pharmaceutical K.K, and Novartis Pharma K.K. NU received honoraria from Nippon Shinyaku Co., Ltd., Bristol-Myers Squibb Co. and Janssen Pharmaceutical K.K. KO received an honorarium from Takeda Pharmaceutical Co., Ltd. SY received honoraria from Janssen Pharmaceutical K.K. and Bristol-Myers Squibb Co. HH received honoraria from CLS Behring K.K. and Takeda Pharmaceutical Co., Ltd. HS received honoraria from Takeda Pharmaceutical Co., Ltd., Fujimoto Pharmaceutical Corp., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Sanofi K.K., AbbVie G.K. and Novartis Pharma K.K., as well as grants from Bristol-Myers Squibb Co., Ono Pharmaceutical Co., Ltd. and AbbVie G.K. NH received personal fees from Otsuka Pharmaceutical K.K. and Chugai Pharmaceutical Co., Ltd. and grants from Chugai Pharmaceutical Co., Ltd., Teijin Pharma Corp., Kyowa Kirin Co., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., AbbVie G.K., Shionogi Pharma and Asahi Kasei Pharma Corp. TI received honoraria from Bristol-Myers Squibb Co., CSL Behring, Janssen Pharmaceutical, Novartis Pharma, Takeda Pharmaceutical Co and AbbVie G.K. CS received honoraria from Janssen Pharmaceutical K.K., Bristol-Myers Squibb Co. and Sanofi K.K. AT-K received honoraria from Nippon Shinyaku Co., Ltd., Bristol-Myers Squibb Co., Janssen Pharmaceutical K.K., Otsuka Pharmaceutical K.K. and Megakaryon Corp., as well as personal fees from Ono Pharmaceutical Co., Ltd., COGNOA Corp., and PharmaEssentia Corp. JK is a consultant for Janssen Pharmaceutical, Pfizer, AbbVie and Bristol Myers Squibb; has received research funding from Kyowa Kirin, Chugai Pharmaceutical, Asahi Kasei, Sumitomo Pharma, Otsuka Pharmaceutical, Mochida Pharmaceutical and the Japan Blood Products Organization; and has received honoraria from Janssen Pharmaceutical, Kyowa Kirin, Chugai Pharmaceutical, Ono Pharmaceutical Co., Ltd. , Sanofi. K.K., Astra Zeneca. K.K., Astellas. K.K., Eisai Co. Ltd., AbbVie G.K., Novartis, Daiichi Sankyo, Amgen, Otsuka Pharmaceutical and BMS. IM received honoraria from AstraZeneca K.K., AbbVie G.K., Otsuka Pharmaceutical K.K., Novartis Pharma K.K., Pfizer Japan Inc., Janssen Pharmaceutical K.K., Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Co., as well as grants from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Taiho Pharmaceutical, AbbVie GK., Otsuka Pharmaceutical K.K., Asahi Kasei Pharma Corporation, Sumitomo Pharma Co., Ltd. and Kyowa Kirin Co. MH received honoraria from Novartis Pharma K.K., Bristol-Myers Squibb Co., Otsuka Pharmaceutical K.K. and Kyowa Kirin Co.; personal fees from LabCorp Drug Development Japan Co., Ltd.; and grants from Otsuka Pharmaceutical K.K., Kyowa Kirin Co., Sekisui Medical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd. and Taiho Pharmaceutical. The other authors have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}